Rising incidence of colorectal cancer in individuals younger than 50 and increasing mortality from rectosigmoid cancer in England

2021 ◽  
Author(s):  
Oon‐Hui Ng ◽  
Raimundas Lunevicius ◽  
James D. Arthur
2020 ◽  
Vol 33 (05) ◽  
pp. 298-304
Author(s):  
Blake Read ◽  
Patricia Sylla

AbstractDespite the steady decline in the incidence of colorectal cancer (CRC) and cancer-related mortality in Americans of 50 years and older over the last few decades, there has been a disturbing trend of steadily rising incidence in early-onset colorectal cancer (EOCRC), defined as CRC in those younger than 50 years. With the incidence of EOCRC increasing from 4.8 per 100,000 in 1988 to 8.0 per 100,000 in 2015, and with the decreased rates in those older than 50 years largely attributed to improved screening in the older population, new screening recommendations have recently lowered the age for screening average-risk individuals from 50 to 45. EOCRC has been found to present differently from late-onset CRC, with a higher proportion of patients presenting with left-sided and rectal cancer, more aggressive histological features, and more advanced stage at the time of diagnosis. This article reviews the most recent evidence from population-based studies and institutional series, as well as the newest screening guidelines, and provides an up-to-date summary of our current understanding of EOCRC, from clinical presentation to tumor biology and prognosis, and future directions in treatment and prevention.


2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 1587-1587
Author(s):  
Daniel Wang Ying ◽  
David R Risser ◽  
Patricia Thompson ◽  
Neda Zarrin-Khameh ◽  
Melissa Bondy ◽  
...  

2017 ◽  
Vol 99 (8) ◽  
pp. e225-e226 ◽  
Author(s):  
A Gonzaga-López ◽  
J Muñoz-Rodriguez ◽  
A Ruiz-Casado

Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier’s gangrene.


Author(s):  
Louise C. Connell ◽  
José Mauricio Mota ◽  
Maria Ignez Braghiroli ◽  
Paulo M. Hoff

2014 ◽  
Vol 30 (1) ◽  
pp. 6-13 ◽  
Author(s):  
Joanne P Young ◽  
Aung Ko Win ◽  
Christophe Rosty ◽  
Ingrid Flight ◽  
David Roder ◽  
...  

2018 ◽  
Vol 154 (6) ◽  
pp. S-71-S-72
Author(s):  
Elisabeth F. Peterse ◽  
Reinier Meester ◽  
Rebecca Siegel ◽  
Jennifer Chen ◽  
Andrea Dwyer ◽  
...  

2020 ◽  
Vol 11 (4) ◽  
pp. e00160
Author(s):  
Hisham Hussan ◽  
Arsheya Patel ◽  
Melissa Le Roux ◽  
Zobeida Cruz-Monserrate ◽  
Kyle Porter ◽  
...  

Author(s):  
Naohiko Akimoto ◽  
Tomotaka Ugai ◽  
Rong Zhong ◽  
Tsuyoshi Hamada ◽  
Kenji Fujiyoshi ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1571-1571
Author(s):  
Hanyu Chen ◽  
Zitong Li ◽  
Xiaobin Zheng ◽  
Jinhee Hur ◽  
Xiaoyu Zong ◽  
...  

1571 Background: The etiology and contributors to the rising incidence of early-onset colorectal cancer (CRC diagnosed under age 50), driven largely by distal and rectal cancer, remain largely unknown. Metabolic syndrome is associated with higher risk of CRC diagnosed at older ages; however, its association with early-onset CRC remains unclear. Methods: We conducted a nested case-control study among participants aged 18-50 years with ≥2 years of enrollment and prescription drug coverage in the IBM MarketScan Commercial Databases (2006-2015). Incident CRC cases were identified using ICD-9-CM diagnosis codes. Controls without any cancer were identified using frequency matching on age, sex, geographical region, and duration of insurance enrollment. Metabolic syndrome was defined using either ICD-9-CM diagnosis codes or the presence of at least 3 of the following: obesity, hypertension, hyperlipidemia, and hyperglycemia/type 2 diabetes. In addition to ICD-9-CM codes, hypertension, hyperlipidemia, and hyperglycemia/type 2 diabetes were also defined based on regular use of medications. Multivariable logistic regressions were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 4,673 early-onset CRC and 40,832 controls were included. Metabolic syndrome was associated with increased risk of early-onset CRC (OR: 1.33, 95% CI 1.16-1.52), after adjusting for a range of potential confounders. The number of metabolic comorbid conditions was positively associated with risk of early-onset CRC in a dose-response fashion. Compared to individuals without any conditions, individuals with 1, 2, ≥3 metabolic conditions had a 13% (OR: 1.13, CI 1.04-1.22), 18% (OR: 1.18, CI 1.07-1.31), and 40% (OR: 1.40, CI 1.22-1.61) higher risk of early-onset CRC (Ptrend<0.001), respectively. These associations were driven by proximal (OR for ≥2 vs 0 metabolic comorbid conditions: 1.40, CI 1.15-1.69) and distal colon cancer, OR ≥2 vs 0: 1.25, CI 1.03-1.53), but not rectal cancer (OR≥2 vs 0: 1.07, CI 0.92-1.24). Conclusions: Metabolic syndrome and metabolic comorbid conditions were associated with increased risk of early-onset CRC, largely driven by proximal and distal colon cancer. Metabolic dysregulations may contribute to the rising incidence of early-onset CRC.


Sign in / Sign up

Export Citation Format

Share Document